As a potential treatment of COVID-19: Montelukast
Non-conventional
| WHO COVID | ID: covidwho-271110
ABSTRACT
It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection.
Search on Google
Collection:
Databases of international organizations
Database:
WHO COVID
Document Type:
Non-conventional
Similar
MEDLINE
...
LILACS
LIS